Your cart is currently empty!
by Hugo Gagnon, CSO, Allumiqs
Recent advances in gene therapy – such as CRISPR/Cas9-based tools – are allowing researchers to introduce or modify genes with unprecedented feasibility. These technologies are hugely exciting from a therapeutic standpoint, particularly in addressing rare and chronic diseases. The ability to potentially heal lethal diseases based on genetic variants, such as muscular dystrophy, cystic fibrosis, and Huntington’s disease, explains the hype around these technologies. In addition, the versatility of gene therapy approaches seems endless.